Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer

(2017) Irene Yushing Chong et al.   GUT

Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma

(2017) Jin Wang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

High expression of Bruton’s tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma

(2017) Chenglong Yue et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Integrated genomic characterization of oesophageal carcinoma

(2017)   NATURE

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma

(2017) Christian Grommes et al.   Cancer Discovery

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2016) B. Escudier et al.   ANNALS OF ONCOLOGY

Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment

(2016) Andrew Stiff et al.   CANCER RESEARCH

A randomized, multicenter, double-blind, placebo-controlled study of the Bruton tyrosine kinase inhibitor, ibrutinib, versus placebo in combination with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE).

(2016) Margaret A. Tempero et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

(2016) Kei Muro et al.   LANCET ONCOLOGY

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

(2016) Asher Chanan-Khan et al.   LANCET ONCOLOGY

Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells

(2016) X. Wang et al.   MOLECULAR CANCER THERAPEUTICS

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation

(2016) Aoli Wang et al.   Oncotarget

Preclinical investigation of ibrutinib, a Bruton’s kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes

(2016) Li Wei et al.   Oncotarget

First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

(2015) Y.-L. Wu et al.   ANNALS OF ONCOLOGY

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

(2015) S. M. Jaglowski et al.   BLOOD

Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse

(2015) S. Bernard et al.   BLOOD

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer

(2015) Leila Kokabee et al.   CANCER BIOLOGY & THERAPY

Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma

(2015) D. Masso-Valles et al.   CANCER RESEARCH

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

(2015) Wyndham H Wilson et al.   NATURE MEDICINE

Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

(2015) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

(2015) Jan A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

(2015) Idit Sagiv-Barfi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targets for Ibrutinib Beyond B Cell Malignancies

(2015) A. Berglöf et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer

(2015) A. J. Gunderson et al.   Cancer Discovery

Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer

(2015) Muhammad Ary Zucha et al.   Oncotarget

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

(2015) Hong Wu et al.   Oncotarget

European cancer mortality predictions for the year 2014

(2014) M. Malvezzi et al.   ANNALS OF ONCOLOGY

Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells

(2014) Nicole Grabinski et al.   INVESTIGATIONAL NEW DRUGS

HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison

(2014) T. Koopman et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Deploying Ibrutinib to Lung Cancer: Another Step in the Quest Towards Drug Repurposing

(2014) E. B. Haura et al.   JNCI-Journal of the National Cancer Institute

Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non–Small Cell Lung Cancer Cells

(2014) Wen Gao et al.   JNCI-Journal of the National Cancer Institute

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

(2014) Yuankai Shi et al.   Journal of Thoracic Oncology

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

(2014) Anas Younes et al.   LANCET ONCOLOGY

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

(2013) J. A. Dubovsky et al.   BLOOD

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia

(2013) S. A. Rushworth et al.   BLOOD

A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis

(2013) Cheryl Eifert et al.   GENES CHROMOSOMES & CANCER

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB

(2012) Stuart A. Rushworth et al.   CELLULAR SIGNALLING

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug

(2012) Simona Caporali et al.   Journal of Translational Medicine

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

(2011) S. E. M. Herman et al.   BLOOD

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

TEC family kinases in health and disease - loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK

(2011) Alamdar Hussain et al.   FEBS Journal

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

(2011) Masahiro Fukuoka et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence ofEGFRExon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas

(2011) Sandra P. D'Angelo et al.   JOURNAL OF CLINICAL ONCOLOGY

Crosstalk between Mast Cells and Pancreatic Cancer Cells Contributes to Pancreatic Tumor Progression

(2010) M. J. Strouch et al.   CLINICAL CANCER RESEARCH

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer

(2009) Anna V. Hoekstra et al.   GYNECOLOGIC ONCOLOGY

Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain

(2009) Abdalla J. Mohamed et al.   IMMUNOLOGICAL REVIEWS